Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig plus carboplatin and pemetrexed versus standard-of-care therapy in unresectable pleural mesothelioma
NL-OMON58763Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of volrustomig in pleural mesothelioma (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Started May 2024; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON58763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58763.